Abstract
Introduction

Stroke remains a great socioeconomic burden for developed and developing countries. Strokes are currently classified into two broad categories: ischemic and haemorrhagic. Ischemic attacks, provoked by either thrombosis or embolism, account for 85% of all stroke cases and are closely related -among other risk factors
-with the existence of complicated atherosclerotic plaques of carotid arteries [2, 3] . Clinical and experimental data suggest that plaques with rupture or ulceration and intraplaque haemorrhagedefined as 'vulnerable' or 'unstable' plaques -are at high risk of producing thromboembolic events in cerebral circulation [4, 5] . Therefore, it remains crucial to unravel the critical factors that determine the progression of atherosclerotic plaques to instability. [8] and angiogenic [9] role, the control over smooth muscle cells migration [10] and the suppression of collagen synthesis [11] . The 
Basic fibroblast growth factor (bFGF/FGF-2) -the prototypic member of a family comprising over 20 related polypeptides [6] -has been detected in human atherosclerotic plaques and is synthesized by three cell types: endothelial cells, vascular smooth muscle cells (VSMCs) and macrophages [7]. bFGF, along with other growth factors, such as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), has been implicated in the pathogenesis of atherosclerosis through its mitogenic
Materials and methods
Tissue samples
Immunoblot analysis Protein extraction
Total protein extraction from cells was performed according to previously described protocols [19] . 
SDS-PAGE
NF-B activation assay
For the luciferase reporter assay the HVTs-SM1 VSMCs were transfected with the NF-B Luc plasmid [20] (a generous gift from Dr. E. Andreakos) and incubated in serum-free medium in the presence or absence of 100 ng/ml recombinant human bFGF (CN 233-FB/CF; RD Systems, AntiSel). Luciferase activity was measured using a luciferase assay system (Promega, SB Biotechnology, Athens, Greece), according to the manufacturer's instructions.
Statistical analysis
Spearman correlation and Mann-Whitney tests were employed for the statistical analysis. All calculations were performed with the SPSS 10.0 software. (Fig. 1c) (Fig. 1c and d) .
Results bFGF expression-dependent up-regulation of iNOS and MMP-9 is associated with atherosclerotic plaque instability
We next analysed the same tissue panel for MMP-9 and iNOS expression. Our IHC analysis revealed cytoplasmic staining for both molecules in VSMCs (Fig. 1e ) that was statistically higher in unstable plaques (P ϭ 0.045 for MMP-9 and P ϭ 0.031 for iNOS, Mann-Whitney test) in accordance with our previously published data [25] . Analogous differences in expression were also detected by immunoblot analysis (Fig. 1f) . Importantly, bFGF expression correlated in a statistically significant manner both with MMP-9 and iNOS expression in VSMCs (P ϭ 0.046 and P Ͻ 0.001, respectively, Spearman correlation), providing primary evidence that bFGF could regulate molecules associated with plaque vulnerability (Fig. 1g) .
The above-described in vivo association was subsequently recapitulated in vitro by treatment of HVTs-SM1 VSMCs with recombinant bFGF, mimicking the in vivo autocrine action of bFGF. bFGF addition in the culture media led to up-regulation of iNOS and MMP-9 (Fig. 1h) , supporting the in vivo observed statistical correlation. (Fig. 2b) . In contrast, only subtle differences in the p42/p44 (phosphorylated extracellular signal-regulated kinase, pERK) expression were noted (Fig. 2b) (Fig. 2c) . Therefore, the MAPK pathway that mediates the mitogenic effects of bFGF seems to have no implication in the induction of MMP-9 and iNOS in VSMCs.
NF-B mediates the bFGF effects related to plaque instability
. To the best of our knowledge, this is the first demonstration that bFGF can induce activation of NF-B in human VSMCs. Furthermore, iNOS and MMP-9 upregulation by bFGF was specifically mediated via NF-B, because the expression of both these molecules returned to control levels after RelA/p65 gene silencing. In contrast, their expression levels remained unaffected by the addition of the MAPK pathway inhibitor PD98059
The (Fig. 2f) . In the latter cases, with IHC nuclear localization of NF-B, p65-pSer536 levels were markedly increased (Fig. 2f) (Fig. 2g) . (Fig. 1b) (Fig. 1b) In concert with the above, our analysis revealed that both MMP-9 and iNOS expression levels were higher in unstable atherosclerotic plaques (P ϭ 0.045 for MMP-9 and P ϭ 0.031 for iNOS, MannWhitney test) (Fig. 1e and f) . Moreover, their expression significantly correlated with bFGF expression (P ϭ 0.046 and P Ͻ 0.001, respectively, Spearman correlation) (Fig. 1g) , while in vitro bFGF treatment led to up-regulation of MMP-9 and iNOS (Fig. 1h) (Fig. 2c) , plays no role in MMP-9 and iNOS up-regulation that is instead specifically mediated by NF-B activation (Fig. 2a and b) , as validated also by the corresponding inhibition and silencing experiments performed (Fig. 2c) . Additionally, we showed that bFGF treatment leads to phosphorylation of the RelA/p65 subunit of NF-B at Ser536 (Fig. 2d-f) , which enhances NF-B transcriptional activity [26] . In agreement, the in situ analysis demonstrated nuclear localization of NF-B and augmented nuclear levels of p65-pSer536 in unstable atherosclerotic plaques that were significantly correlated with increased bFGF, FGFR-1, iNOS and MMP-9 expression (Fig. 2g) 
above-described mechanism was also supported by our in vivo experiments. The carotid atherosclerotic plaques from our database were immunohistochemically analysed for NF-B expression. VSMCs stained positive for NF-B and the staining was either solely cytoplasmic or concomitantly cytoplasmic and nuclear (Fig. 2d). The nuclear localization of NF-B, as detected by IHC analysis, is indicative for its activity [27]. This subcellular distribution was further confirmed by detection of RelA phosphorylated at Ser536 (p65-pSer536) employing IF analysis (Fig. 2e) and immunoblotting in extracts from carotid clinical specimens displaying sole cytoplasmic versus cytoplasmic/nuclear IHC staining
. Notably, higher fraction of cells with concomitant cytoplasmic and nuclear NF-B nuclear distribution was observed in unstable plaques versus stable ones (P ϭ 0.025, data not shown). Subsequently, the expression of bFGF, FGFR-1/-2, MMP-9 and iNOS was stratified according to NF-B subcellular distribution. The statistical analysis revealed significant increase in their expression levelswith the exception of FGFR-2 -when NF-B localization was nuclear, confirming our in vitro observations
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Fig. 1 bFGF expression is increased in unstable carotid atherosclerotic plaques and correlates with FGFR-1, MMP-9 and iNOS expression. (A) Representative pictures of bFGF immunohistochemical expression in stable and unstable plaques. Insets represent higher magnification of the selected areas. (B) Boxplots depict differences in bFGF expression according to plaque stability and patients' symptoms. (C) Representative pictures of FGFR-1/2 expression in stable and unstable carotid atherosclerotic plaques. (D) Boxplots showing differences in FGFR-1 and FGFR-2 expression between stable and unstable carotid plaques. (E) Representative pictures from two cases with low and high expression levels of iNOS and MMP-9, respectively. (F) Representative immunoblotting analysis for iNOS and MMP-9 in carotid specimens. (G) Scatterplots showing the correlation among bFGF and iNOS and MMP-9 expression. (H) Immunoblotting analysis of human VSMCs for iNOS and MMP-9 expression, before and after the addition of recombinant bFGF in the culture medium.
Discussion
Several growth factors have been implicated in the pathogenesis of atherosclerosis. bFGF is one of these and according to several animal models enhances VSMC proliferation and neointima formation as well as vasa vasorum proliferation through its mitogenic and angiogenic activity [8, 9, 28, 29]. Studies in patients have shown the presence of high serum levels of bFGF, suggesting a potential relation connecting bFGF with active atheromatosis [30] and plaque instability [16]. The latter is of major clinical © 2010 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 NF-B specifically mediates the up-regulation of MMP-9 and iNOS by bFGF treatment. (A) NF-B luciferase reporter assay of VSMCs transfected either with empty vector or firefly luciferase reporter plasmid driven by five consecutive artificial NF-B-binding sites [NF-B-luc). (B) Immunoblotting analysis of p65-pSer536 and pERK in VSMCs at 30, 60 and 180 min. after addition of bFGF in the culture medium. Actin serves as loading control. The histogram depicts the quantitative estimation of p65-pSer536 expression levels after densitometric analysis. (C) iNOS and MMP-9 immunoblotting analysis in VSMCs treated with bFGF along with either MAPK inhibitor PD98059 or siRelA. The histogram depicts the quantitative estimation, after densitometric analysis, of iNOS and MMP-9 expression levels with several treatments. (D) Representative cases depicting sole cytoplasmic (stable plaque) and cytoplasmic/nuclear (unstable plaque) NF-B IHC staining in carotid atherosclerotic plaques. (E) IF analysis of case 1 depicting cytoplasmic/nuclear NF-B localization. (F) Immunoblotting analysis for total p65-pSer536 levels in two representative
